Cargando…
Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/− mice
The TOR (Target of Rapamycin) pathway accelerates cellular and organismal aging. Similar to rapamycin, p53 can inhibit the mTOR pathway in some mammalian cells. Mice lacking one copy of p53 (p53+/− mice) have an increased cancer incidence and a shorter lifespan. We hypothesize that rapamycin can del...
Autores principales: | Komarova, Elena A., Antoch, Marina P., Novototskaya, Liliya R., Chernova, Olga B., Paszkiewicz, Geraldine, Leontieva, Olga V., Blagosklonny, Mikhail V., Gudkov, Andrei V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517941/ https://www.ncbi.nlm.nih.gov/pubmed/23123616 |
Ejemplares similares
-
New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53(−/−) mice by delaying carcinogenesis
por: Comas, Maria, et al.
Publicado: (2012) -
Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet
por: Leontieva, Olga V, et al.
Publicado: (2014) -
Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging
por: Leontieva, Olga V., et al.
Publicado: (2012) -
Elimination of Proliferating Cells Unmasks the Shift from Senescence to Quiescence Caused by Rapamycin
por: Leontieva, Olga V., et al.
Publicado: (2011) -
As predicted by hyperfunction theory, rapamycin treatment during development extends lifespan
por: Blagosklonny, Mikhail V.
Publicado: (2022)